Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

NETWORK × Small Cell Lung Carcinoma × pembrolizumab × Clear all

Phase

Status

Sponsor Class

INDUSTRY 24 OTHER 6 NIH 1 NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lung Neoplasms 3 Neoplasm Metastasis 2 Carcinoma, Non-Small-Cell Lung 2 Squamous Cell Carcinoma of Head and Neck 1 Small Cell Lung Carcinoma 1 Prostate Cancer Metastatic 1 Oropharyngeal Neoplasms 1 Oligometastatic Squamous Cell Carcinoma of the Head and Neck 1 Neoplasm, Residual 1 Mouth Neoplasms 1 Mesothelioma 1 Melanoma 1 Leukemia, Myeloid, Chronic-Phase 1 Laryngeal Neoplasms 1 Hypopharyngeal Neoplasms 1 Hodgkin Disease 1 Gallbladder Neoplasms 1 Colorectal Neoplasms 1 Carcinoma 1 Breast Neoplasms 1 Biliary Tract Neoplasms 1 Anatomic Stage I Breast Cancer AJCC v8 1

Interventions

Cisplatin 3 Taxes 2 Psychiatric Rehabilitation 2 Paclitaxel 2 Magnetic Resonance Spectroscopy 2 Etoposide 2 rubitecan 1 pembrolizumab 1 monalizumab 1 marimastat 1 etoposide phosphate 1 durvalumab 1 ceralasertib 1 carfilzomib 1 atezolizumab 1 Watchful Waiting 1 Sunitinib 1 Specimen Handling 1 Radiotherapy, Conformal 1 Polymerase Chain Reaction 1 Platinum Compounds 1 PM 01183 1 Nivolumab 1 NK Cell Lectin-Like Receptor Subfamily C 1 Mental Status and Dementia Tests 1 Isotretinoin 1 Irinotecan 1 Ipilimumab 1 Introns 1 Interferon-alpha 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02580994 2023-12-11

REACTION

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Completed

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡